Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
Olivier Trédan
,
Magali Provansal
,
Cyril Abdeddaim
,
Audrey Lardy-Cleaud
,
Anne-Claire Hardy-Bessard
,
Elsa Kalbacher
,
Anne Floquet
,
Laurence Venat-Bouvet
,
Alain Lortholary
,
Oana Pop
,
Jean-Sébastien Frenel
,
Mathilde Cancel
,
Rémy Largillier
,
Christophe Louvet
,
Benoît You
,
Alain Zannetti
,
Amelie Anota
,
Isabelle Treilleux
,
Daniel Pissaloux
,
Aurélie Houlier
,
Aude-Marie Savoye
,
Marie-Ange Mouret-Reynier
(1)
,
Jérôme Meunier
,
Charles-Briac Levaché
,
Fabien Brocard
,
Isabelle Ray-Coquard
Olivier Trédan
- Function : Author
Magali Provansal
- Function : Author
Cyril Abdeddaim
- Function : Author
Audrey Lardy-Cleaud
- Function : Author
Anne-Claire Hardy-Bessard
- Function : Author
Elsa Kalbacher
- Function : Author
Anne Floquet
- Function : Author
Laurence Venat-Bouvet
- Function : Author
Alain Lortholary
- Function : Author
Oana Pop
- Function : Author
Jean-Sébastien Frenel
- Function : Author
Mathilde Cancel
- Function : Author
Rémy Largillier
- Function : Author
Christophe Louvet
- Function : Author
Benoît You
- Function : Author
Alain Zannetti
- Function : Author
Amelie Anota
- Function : Author
Isabelle Treilleux
- Function : Author
Daniel Pissaloux
- Function : Author
Aurélie Houlier
- Function : Author
Aude-Marie Savoye
- Function : Author
Jérôme Meunier
- Function : Author
Charles-Briac Levaché
- Function : Author
Fabien Brocard
- Function : Author
Isabelle Ray-Coquard
- Function : Author